Adipokine Omentin1: A Diagnostic Tool in Breast Cancer

Introduction: Breast cancer is the most frequent solid malignancy in women. Omentin1 is synthesized by visceral adipose tissue, placenta, and ovary and its production is altered in some cancers. The aim of this study was to assess omentin1 as a diagnostic marker in patients with breast cancer. Methods: The participants of the study included 90 women (45 patients with breast cancer and 45 healthy women as control group). In addition to anthropometric and blood parameters analysis, omentin1 serum levels were measured by enzymelinked immunosorbent assays method. Receiver operator characteristic curve and positive and negative predictive values (PPV and NPV) were calculated to define diagnostic accuracy. Results: Serum omentin1 level in breast cancer patients (157 ng/L ± 66 ng/L, mean ± SD) was significantly lower than that of the control group (217 ng/L±75 ng/L, mean ± SD). There was no significant correlation between omentin1 levels and anthropometric and blood parameters. The best cutoff point for the diagnosis of breast cancer was at 146 ng/L. The sensitivity and specificity for omentin1 with 95% CI (0.611 to 0.837) were 60% and 85%, respectively. Calculated PPV and NPV at the 146 ng/L cutoff point were 88.8% and 51.5%, respectively. Conclusion: Breast cancer patients had significantly lower serum level of omentin1 than healthy women. Omentin1 may be beneficial as a screening test along with the earlyapproved methods in the diagnosis of patients with breast cancer.